ALXP
ALMKT
Market cap32mUSD
Oct 21, Last price
1.04EUR
Name
Mauna Kea Technologies SAS
Chart & performance
P/E
—
P/S
6.05
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-8.03%
Revenues
8m
-30.58%
Net income
-10m
L+179.15%
CFO
-6m
L+739.84%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Headquartered in Paris, France, Mauna Kea Technologies S.A. commenced operations in 2000. This company specializes in developing and commercializing medical devices, with a broad market presence spanning Europe, the Middle East, Africa, the Americas, and Asia. A primary focus for Mauna Kea Technologies is creating and distributing instruments designed to enable the real-time detection and visualization of cellular irregularities. These innovative tools are utilized during standard endoscopic examinations of the gastrointestinal and pulmonary systems. Their leading product, Cellvizio, stands as a prime example: it is an advanced confocal miniprobe endomicroscopy system. Cellvizio delivers exceptionally detailed, cellular-level images of tissues to both physicians and scientific researchers.
Key people
Sacha Loiseau
Chairman of the Board · since 2018
Chief Executive Officer, Director · since 2018
Deputy Chief Executive Officer, Chief Financial Officer · since 2018
Francois Lacombe
Chief Scientific Officer · since 2005
Bruno Villaret
Vice President of International Sales · since 2017
Severine Cadiou
Director of Human Resources · since 2017
Aline Criton
Regulatory and Clinical Affairs and Scientific Communication Director
Veronique Dentan
Director of Operations
Christopher D. McFadden
Director · since 2018
Independent Director · since 2016
Molly O'Neill
Independent Director · since 2018
Jennifer F. Tseng
Independent Director · since 2017
Headquarters & legal address
9 RUE D'ENGHIEN
PARIS 75010
FR
PARIS 75010
FR
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||